RASSF1 antikoerper, zgc:92505 antikoerper, wu:fc17f02 antikoerper, zgc:112224 antikoerper, 123F2 antikoerper, NORE2A antikoerper, RASSF1A antikoerper, RDA32 antikoerper, REH3P21 antikoerper, AA536941 antikoerper, AU044980 antikoerper, Rassf1A antikoerper, Rassf1B antikoerper, Rassf1C antikoerper, NPR2-like, GATOR1 complex subunit antikoerper, Ras association (RalGDS/AF-6) domain family 1 antikoerper, Ras association domain family member 1 antikoerper, putative rassf1 antikoerper, Ras association domain family member 1 L homeolog antikoerper, Ras association (RalGDS/AF-6) domain family member 1 antikoerper, NPRL2 antikoerper, rassf1 antikoerper, RASSF1 antikoerper, Smp_157340 antikoerper, rassf1.L antikoerper, Rassf1 antikoerper
Hintergrund
The tumor suppressor gene RASSF1A (3p21.3), human Ras association domain family 1A, is expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, small intestine, colon, and peripheral blood leukocytes. RASSF1A expression is inhibited by hypermethylation of the CpG island including the promoter and early transcribed regions of the human RASSF1A gene. Hypermethylated RASSF1A promoter is observed in primary tumors. Furthermore, RASSF1A is related with cell cycle regulation, apoptosis and microtubule stability.